Novo Holdings

Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on anti-infective products, developing and manufacturing fermented and semi-synthetic active pharmaceutical ingredients and finished dosage forms for global pharmaceutical clients. It offers contract manufacturing services for antibiotics, from custom synthesis of clinical trial material to large-scale production of marketed products, along with stability testing, filling and packaging of dry powder filled vials and lyophilized vials. The company is a leading supplier of vancomycin and colistimethate sodium and operates manufacturing facilities in Europe and Asia with a global customer base across more than 70 countries. Xellia adheres to current Good Manufacturing Practice and maintains regulatory approvals from relevant authorities.

Avilex Pharma is a Danish biotechnology company spun out from the University of Copenhagen. It leverages technology from the Department of Drug Design and Pharmacology to develop dimeric peptides that target PSD95 for the treatment of neuropathic pain. The company is also developing inhibitors and neuroprotectants designed to modulate intracellular scaffolding and postsynaptic density proteins to aid recovery after ischemic stroke. Based in Copenhagen, Denmark, Avilex Pharma has backing from Novo Seeds and the Wellcome Trust.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Adenium Biotech ApS is a Copenhagen-based biopharmaceutical company founded in 2011, specializing in the development and commercialization of novel antibiotics aimed at treating multi-drug resistant bacterial infections. The company focuses on addressing hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Its lead product, Arenicin, is a 21-amino acid antimicrobial peptide derived from the lugworm, demonstrating strong efficacy against Gram-negative pathogens while maintaining a broad therapeutic window. Adenium Biotech operates as a semi-virtual company, relying on a small team of experts supported by an international scientific advisory board to advance its clinical development programs toward regulatory approval.

EpiTherapeutics is a biotechnology company focused on developing innovative cancer therapies that leverage the science of epigenetics. Founded on research conducted by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen, the company specializes in small-molecule therapies targeting enzymes that regulate transcription in cancer cells. EpiTherapeutics has created a library of selective small molecule inhibitors, with a particular emphasis on histone demethylases, which play a critical role in gene transcription. The company's lead compounds are currently in pre-clinical development, aimed at addressing specific types of cancer.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.